Quinazolinedione SIRT6 inhibitors sensitize cancer cells to chemotherapeutics

European Journal of Medicinal Chemistry

Volumn 102, Issue , 2015, Pages 530-539

  Sociali, Giovanna ^a   Galeno, Lauretta ^b   Parenti, Marco Daniele ^b,c   Grozio, Alessia ^a   Bauer, Inga ^b   Passalacqua, Mario ^a   Boero, Silvia ^b,d   Donadini, Alessandra ^b   Millo, Enrico ^a   Bellotti, Marta ^a   Sturla, Laura ^a   Damonte, Patrizia ^b   Puddu, Alessandra ^b   Ferroni, Claudia ^e   Varchi, Greta ^e   Franceschi, Claudio ^c,e   Ballestrero, Alberto ^b,d   Poggi, Alessandro ^d   Bruzzone, Santina ^a   Nencioni, Alessio ^b,d   Del Rio, Alberto ^c,e   more..

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

^e CNR   (Italy)

Author keywords

Anticancer drugs; Chemotherapy; Molecular design; NAD dependent deacetylases; Quinazolinedione; Sirtuins; Small molecule inhibitors

Indexed keywords

ANTINEOPLASTIC AGENT; BRCA2 PROTEIN; GEMCITABINE; HISTONE H2AX; HISTONE H3; MESYLIC ACID METHYL ESTER; OLAPARIB; QUINAZOLINE DERIVATIVE; QUINAZOLINEDIONE SIRTUIN 6 INHIBITOR; SIRTUIN 1; SIRTUIN 2; SIRTUIN 6; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ENZYME INHIBITOR; PHTHALAZINE DERIVATIVE; PIPERAZINE DERIVATIVE; QUINAZOLINONE DERIVATIVE; SIRT6 PROTEIN, HUMAN; SIRTUIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CELL DEATH; CELL VIABILITY; CHEMOSENSITIZATION; COMPETITIVE INHIBITION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA DAMAGE; DRUG POTENTIATION; DRUG SELECTIVITY; GLUCOSE TRANSPORT; HISTONE ACETYLATION; HUMAN; HUMAN CELL; IC50; PERIPHERAL BLOOD MONONUCLEAR CELL; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; METABOLISM; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TUMOR CELL CULTURE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL DEATH; CELL SURVIVAL; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; HUMANS; MOLECULAR STRUCTURE; PHTHALAZINES; PIPERAZINES; QUINAZOLINONES; SIRTUINS; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 84940179025     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2015.08.024     Document Type: Article

References (33)

1. J.-P. Etchegaray L. Zhong R. Mostoslavsky The histone deacetylase SIRT6: at the crossroads between epigenetics, metabolism and disease Curr. Top. Med. Chem. 13 2013 2991 3000
2. F. Andreoli A. Del Rio Physicochemical modifications of histones and their impact on epigenomics Drug Discov. Today 19 2014 1372 1379
3. R. Mostoslavsky K.F. Chua D.B. Lombard W.W. Pang M.R. Fischer L. Gellon, et al. Genomic instability and aging-like phenotype in the absence of mammalian SIRT6 Cell 124 2006 315 329
4. R.A. McCord E. Michishita T. Hong E. Berber L.D. Boxer R. Kusumoto, et al. SIRT6 stabilizes DNA-dependent protein kinase at chromatin for DNA double-strand break repair Aging (Albany NY) 1 2009 109 121
5. L. Zhong A. D'Urso D. Toiber C. Sebastian R.E. Henry D.D. Vadysirisack, et al. The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1alpha Cell 140 2010 280 293
6. C. Xiao H.-S. Kim T. Lahusen R.-H. Wang X. Xu O. Gavrilova, et al. SIRT6 deficiency results in severe hypoglycemia by enhancing both basal and insulin-stimulated glucose uptake in mice J. Biol. Chem. 285 2010 36776 36784
7. F. Van Gool M. Gallí C. Gueydan V. Kruys P.-P. Prevot A. Bedalov, et al. Intracellular NAD levels regulate tumor necrosis factor protein synthesis in a sirtuin-dependent manner Nat. Med. 15 2009 206 210
8. + depletion in activated T lymphocytes through Nampt inhibition reduces demyelination and disability in EAE PLoS One 4 2009 e7897
9. H. Jiang S. Khan Y. Wang G. Charron B. He C. Sebastian, et al. SIRT6 regulates TNF-α secretion through hydrolysis of long-chain fatty acyl lysine Nature 496 2013 110 113
10. Z. Lin H. Yang C. Tan J. Li Z. Liu Q. Quan, et al. USP10 antagonizes c-Myc transcriptional activation through SIRT6 stabilization to suppress tumor formation Cell Rep. 5 2013 1639 1649
11. C. Sebastián B.M.M. Zwaans D.M. Silberman M. Gymrek A. Goren L. Zhong, et al. The histone deacetylase SIRT6 is a tumor suppressor that controls cancer metabolism Cell 151 2012 1185 1199
12. U. Thirumurthi J. Shen W. Xia A.M. LaBaff Y. Wei C.-W. Li, et al. MDM2-mediated degradation of SIRT6 phosphorylated by AKT1 promotes tumorigenesis and trastuzumab resistance in breast cancer Sci. Signal 7 2014 ra71
13. J.U. Marquardt K. Fischer K. Baus A. Kashyap S. Ma M. Krupp, et al. Sirtuin-6-dependent genetic and epigenetic alterations are associated with poor clinical outcome in hepatocellular carcinoma patients Hepatology 58 2013 1054 1064
14. M. Khongkow Y. Olmos C. Gong A.R. Gomes L.J. Monteiro E. Yagüe, et al. SIRT6 modulates paclitaxel and epirubicin resistance and survival in breast cancer Carcinogenesis 34 2013 1476 1486
15. Y. Liu Q.R. Xie B. Wang J. Shao T. Zhang T. Liu, et al. Inhibition of SIRT6 in prostate cancer reduces cell viability and increases sensitivity to chemotherapeutics Protein Cell 4 2013 702 710
16. K. Lefort Y. Brooks P. Ostano M. Cario-André V. Calpini J. Guinea-Viniegra, et al. A miR-34a-SIRT6 axis in the squamous cell differentiation network EMBO J. 32 2013 2248 2263
17. M. Ming W. Han B. Zhao N.R. Sundaresan C.-X. Deng M.P. Gupta, et al. SIRT6 promotes COX-2 expression and acts as an oncogene in skin cancer Cancer Res. 74 2014 5925 5933
18. 2+ responses J. Biol. Chem. 287 2012 40924 40937
19. A. Del Rio C. Franceschi M.D. Parenti I. Bauer S. Bruzzone A. Grozio, et al. Quinazolinedione Compounds with a Sirtuin Inhibiting Activity 2014 WO/2014/170875
20. A. Del Rio C. Franceschi M.D. Parenti I. Bauer S. Bruzzone A. Grozio, et al. Compounds with a Sirtuin Inhibiting Activity 2014 WO/2014/170873
21. F. Andreoli A. Del Rio Computer-aided molecular design of compounds targeting histone modifying enzymes Comput. Struct. Biotechnol. J. 13 2015 358 365
22. M.D. Parenti S. Bruzzone A. Nencioni A. Del Rio Selectivity hot-spots of sirtuin catalytic cores Mol. Biosyst. 11 2015 2263 2272
23. M.D. Parenti A. Grozio I. Bauer L. Galeno P. Damonte E. Millo, et al. Discovery of novel and selective SIRT6 inhibitors J. Med. Chem. 57 2014 4796 4804
24. F. Andreoli A.J.M. Barbosa M.D. Parenti A. Del Rio Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectives Curr. Pharm. Des. 19 2013 578 613
25. S. Bruzzone M.D. Parenti A. Grozio A. Ballestrero I. Bauer A. Del Rio, et al. Rejuvenating sirtuins: the rise of a new family of cancer drug targets Curr. Pharm. Des. 19 2013 614 623
26. A. Del Rio A.J.M. Barbosa F. Caporuscio G.F. Mangiatordi CoCoCo: a free suite of multiconformational chemical databases for high-throughput virtual screening purposes Mol. Biosyst. 6 2010 2122 2128
27. P.W. Pan J.L. Feldman M.K. Devries A. Dong A.M. Edwards J.M. Denu Structure and biochemical functions of SIRT6 J. Biol. Chem. 286 2011 14575 14587
28. Z. Mao C. Hine X. Tian M. Van Meter M. Au A. Vaidya, et al. SIRT6 promotes DNA repair under stress by activating PARP1 Science 332 2011 1443 1446
29. C.J. Lord A.N.J. Tutt A. Ashworth Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors Annu. Rev. Med. 66 2014 455 470
30. E. Michishita R.A. McCord E. Berber M. Kioi H. Padilla-Nash M. Damian, et al. SIRT6 is a histone H3 lysine 9 deacetylase that modulates telomeric chromatin Nature 452 2008 492 496
31. Y.K. Yoon M.A. Ali A.C. Wei A.N. Shirazi K. Parang T.S. Choon Benzimidazoles as new scaffold of sirtuin inhibitors: green synthesis, in vitro studies, molecular docking analysis and evaluation of their anti-cancer properties Eur. J. Med. Chem. 83 2014 448 454
32. G. Hoffmann F. Breitenbücher M. Schuler A.E. Ehrenhofer-Murray A novel sirtuin 2 (SIRT2) inhibitor with p53-dependent pro-apoptotic activity in non-small cell lung cancer J. Biol. Chem. 289 2014 5208 5216
33. S. Bruzzone P. Ameri L. Briatore E. Mannino G. Basile G. Andraghetti, et al. The plant hormone abscisic acid increases in human plasma after hyperglycemia and stimulates glucose consumption by adipocytes and myoblasts FASEB J. 26 2012 1251 1260